PCa Commentary | Volume 171 – November 2022
This Commentary explores treatment regimens combining enzalutamide, apalutamide, or darolutamide with androgen deprivation for nmCRPC.
Read MoreSelect Page
Posted by Edward Weber, MD | Nov 2022
This Commentary explores treatment regimens combining enzalutamide, apalutamide, or darolutamide with androgen deprivation for nmCRPC.
Read MorePosted by Edward Weber, MD | Sep 2022
This Commentary looks at ADT and radiotherapy, as well as evolution of cellular resistance to ADT therapy and potential treatment.
Read MorePosted by Edward Weber, MD | Jun 2022
This Commentary looks at developing research on how to use CAR-T cell immunotherapy to treat prostate cancer.
Read MorePosted by Edward Weber, MD | May 2022
This Commentary looks at Lutetium-177 PSMA-617 therapy radioligand therapy for metastatic castration-resistant prostate cancer.
Read MorePosted by Edward Weber, MD | Apr 2022
This Commentary looks at an emerging management trifecta for recurrent prostate cancer: PSMA PET, oligometastatic cancer & focal therapy.
Read More